OakChart

Kestra Medical Technologies Ltd

KMTSHealthcare·Medical Instruments & Supplies·USA·Small·NASD·Nov 11 • 11:48 AM ET

30.45+0.90 (3.05%)
2026-11-11 17:48 CET
Market cap
1,760.05 USD m
Revenue, TTM
106.73 USD m
Net income, TTM
-149.87 USD m
Free cash flow, TTM
-123.21 USD m
EPS diluted, TTM
-2.67
P/E
-
Compare

Price

KMTS against its 20, 50 and 200-day averages
2050200miss
20.0025.0030.00947K1.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26KMTSclose 30.4520-day 29.2250-day 27.23200-day 24.0430.4552w high52w low

4.6% under the 52-week high of 31.91 on 4 Nov 2026. 52-week low 17.34 on 13 Apr 2026. Last 15 sessions, 17.4% high to low

Profile

KMTS
52-week range, 90% of the way up
17.3431.91

Kestra Medical Technologies Ltd. is a commercial-stage, wearable medical device and digital healthcare company. It focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company was founded by Brian Webster and Traci S. Umberger in 2014 and is headquartered in Kirkland, WA.

IndexRUT
Employees443
IPOMar 06, 2025
Beta0.47
ATR, 14d1.78
Rel volume0.29
Short float16.89%
Insider own59.20%
Inst own46.82%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.81B
Enterprise Value1.69B
Income-149.87M
Sales106.73M
Book/sh3.75
Cash/sh3.34
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees443
IPOMar 06, 2025

Ratios

P/E-
Forward P/E-
PEG-
P/S16.99
P/B8.12
P/C9.12
P/FCF-
EV/EBITDA-
EV/Sales15.85
Quick Ratio4.53
Current Ratio4.69
Debt/Eq0.34
LT Debt/Eq0.34
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.67
EPS next Y-2.05
EPS next Q-0.61
EPS this Y-0.79%
EPS next Y16.15%
EPS next 5Y13.25%
EPS past 3/5Y-11.52% -
Sales past 3/5Y131.88% -
EPS Y/Y TTM-5.66%
Sales Y/Y TTM60.72%
EPS Q/Q-49.54%
Sales Q/Q59.88%
EarningsSep 14 AMC
EPS/Sales Surpr.-21.77% 6.76%

Ownership

Insider Own59.20%
Insider Trans-1.45%
Inst Own46.82%
Inst Trans0.15%
ROA-48.85%
ROE-73.74%
ROIC-50.16%
Gross Margin53.89%
Oper. Margin-134.48%
Profit Margin-140.43%
SMA204.23%
SMA5011.81%
SMA20026.68%
Trades-

Technical

Shs Outstand59.27M
Shs Float24.30M
Short Float16.89%
Short Ratio10.22
Short Interest4.10M
52W High31.91 -4.56%
52W Low17.34 75.61%
Volatility8.23% 6.50%
ATR (14)1.78
RSI (14)57.40
Beta0.47
Rel Volume0.29
Avg Volume401.59K
Volume44,426

Performance

Perf Week-0.16%
Perf Month12.90%
Perf Quarter9.77%
Perf Half Y41.96%
Perf YTD14.82%
Perf Year10.49%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.22
Target Price31.12
Prev Close29.55
Price30.45
Change %3.05%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Oct 20, 2026InitiatedEEvercore ISIOutperform$34+11.7%
Aug 10, 2026InitiatedJJP MorganOverweight$30-1.5%
Jul 21, 2026InitiatedOOppenheimerPerform
Nov 18, 2025InitiatedBBTIG ResearchBuy$32+5.1%
Mar 31, 2025InitiatedWWolfe ResearchOutperform$29-4.8%
Mar 31, 2025InitiatedWWells FargoOverweight$28-8.0%
Mar 31, 2025InitiatedSStifelBuy$28-8.0%
Mar 31, 2025InitiatedPPiper SandlerOverweight$27-11.3%
Mar 31, 2025InitiatedGGoldmanNeutral$24-21.2%
Mar 31, 2025InitiatedBBofA SecuritiesBuy$30-1.5%

Peers

Mkt cap
TickerCompanyMkt cap
IRTCiRhythm Holdings Inc2.99B
ATRCAtricure Inc2.88B
BSXBoston Scientific Corp66.37B
MDTMedtronic Plc129.38B
CBLLCeribell Inc1.07B
ABTAbbott Laboratories190.08B
STXSStereotaxis Inc87.36M
NVCRNovoCure Ltd1.44B
IRMDIradimed Corp1.10B
PHGKoninklijke Philips NV ADR29.44B

Insider trading

latest 14 of 92
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Moran Timothy P.Chief Business OfficerNov 03 '26Sale29.563,19294,35263,153Nov 05 05:41 PM
Moran Timothy P.OfficerNov 03 '26Proposed Sale29.563,19294,352Nov 03 04:12 PM
Mahboob VaseemChief Financial OfficerOct 28 '26Option Exercise17.0039,903678,351100,512Oct 29 06:46 PM
Mahboob VaseemChief Financial OfficerOct 27 '26Option Exercise17.0034,809591,75395,418Oct 29 06:46 PM
Mahboob VaseemChief Financial OfficerOct 29 '26Option Exercise17.004,78881,39665,397Oct 29 06:46 PM
Mahboob VaseemChief Financial OfficerOct 28 '26Sale30.4839,9031,216,30360,609Oct 29 06:46 PM
Mahboob VaseemChief Financial OfficerOct 27 '26Sale30.0434,8091,045,78460,609Oct 29 06:46 PM
Mahboob VaseemChief Financial OfficerOct 29 '26Sale30.604,788146,50360,609Oct 29 06:46 PM
Umberger Traci SSee RemarksOct 27 '26Option Exercise17.0030,000510,000225,825Oct 29 06:44 PM
Umberger Traci SSee RemarksOct 27 '26Sale30.0330,000900,882195,825Oct 29 06:44 PM
Mahboob VaseemOfficerOct 29 '26Proposed Sale30.604,788146,503Oct 29 04:37 PM
Mahboob VaseemOfficerOct 28 '26Proposed Sale30.4839,9031,216,393Oct 28 04:36 PM
Mahboob VaseemOfficerOct 27 '26Proposed Sale30.0434,8091,045,785Oct 27 04:12 PM
Umberger Traci SOfficerOct 27 '26Proposed Sale30.0330,000900,881Oct 27 04:09 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
FYCFirst Trust Small Cap Growth AlphaDEX FundAUM: 1.35B
FBCGFidelity Blue Chip Growth ETFAUM: 7.23B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IHIiShares U.S. Medical Devices ETFAUM: 4.07B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
TMSLT. Rowe Price Small-Mid Cap ETFAUM: 3.28B

News

latest 14 of 136
  • Kestra Medical Technologies to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Kestra Medical Technologies Earns Five-Star Rating on Newsweek's List of America's Greatest Mid-Market Companies (GlobeNewswire)
  • Kestra Medical Technologies Ltd (KMTS) (Q1 2027) Earnings Call Highlights: Revenue Jumps 60% as ... (GuruFocus.com)
  • Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results (GlobeNewswire) +5.30%
  • Kestra Medical Technologies Ltd (KMTS) Q1 2027 Earnings Report Preview: What To Look For (GuruFocus.com)
  • Loading…
  • Kestra Names Daniel Finney Vice President of Research & Development (GlobeNewswire)
  • Kestra Medical Technologies to Report First Quarter Fiscal 2027 Financial Results on September 14 (GlobeNewswire)
  • Kestra Appoints Curtis Kopf as Senior Vice President of Customer Experience (GlobeNewswire)
  • Apple downgraded, HPE upgraded: Wall Street's top analyst calls (The Fly) +7.39%
  • Kestra Medical Technologies Ltd (KMTS) Q4 2026 Earnings Call Highlights: Record Revenue Growth ... (GuruFocus.com)
  • Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing (GlobeNewswire)
  • Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2026 Financial Results (GlobeNewswire)
  • Earnings To Watch: Kestra Medical Technologies Ltd (KMTS) Reports Q4 2026 Result (GuruFocus.com)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q12026-09-14-0.750-0.616-0.75030.9729.018
2025Q42026-07-14-0.670-0.590-0.66528.6426.486
2025Q32026-03-17-0.610-0.596-0.61224.5522.877
2025Q22025-12-11-0.640-0.594-0.63822.5720.727
2025Q12025-09-11-0.500-0.610-0.50319.3717.874
2024Q42025-07-15-2.210-0.525-1.06017.2315.676
2024Q32025-04-14-1.250-0.603-0.48415.0915.073
2024Q22025-01-01-0.550--0.47814.78--
2026Q2---0.606--32.099
2026Q3---0.580--35.499
2026Q4---0.524--42.349
2027Q1---0.560--42.896
2027Q2---0.532--44.415
2027Q3---0.522--49.325
2027Q4---0.506--58.505
2028Q1---0.460--61.151

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-5.130-2.287-2.45659.8258.26
2025FY-2.430-2.343-2.43095.1392.97
2026FY--2.449--140.88
2027FY--2.054--196.04
2028FY--1.587--271.63
2029FY--1.110--342.84

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q2S2026-10-1997032.0931.9032.60
2026Q2S2026-10-0987032.0231.9032.10
2026Q2S2026-09-1587032.0331.9032.10
2026Q2S2026-09-1480331.5230.9032.00
2026Q2S2026-09-0180331.5230.9032.00
2026Q2S2026-08-0780331.5230.9032.00
2026Q2S2026-07-2070331.4530.9031.60
2026Q2S2026-07-1560331.4330.9031.60
2026Q2S2026-07-1060031.6230.7932.40
2026Q2S2026-06-0160031.6330.7932.43
2026Q2S2026-05-0862131.6330.7932.43
2026Q2S2026-04-2462231.6230.7932.43
2026Q2S2026-04-1062231.6230.7932.40
2026Q2S2026-04-0662231.6230.7932.43

Estimate history

EPS, annual-1.751-2.036-2.456-2.429-2.6677
Period2022202320242025TTM
EPS, quarterly-0.45-0.478-0.484-1.06-0.503-0.638-0.612-0.665-0.753
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Sales, annual7.6327.81459.81595.126106.73
Period2022202320242025TTM
Sales, quarterly12.78214.7115.0917.23319.37122.56524.55228.63830.971
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Shares, annual49.53449.53451.34958.38459.272
Period2022202320242025MRQ
Shares, quarterly49.53449.53451.34951.34951.34951.44958.34958.38459.272
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue106.7395.1359.8127.817.63
Cost of Goods Sold Incl. D&A49.2246.2635.6027.4518.28
Gross Profit57.5148.8624.210.36-10.65
Selling, General and Administrative Excl. Other201.03183.60130.5985.4269.77
Research and Development22.2819.4815.6515.4915.76
Other Operating Expense0.000.000.000.000.00
Operating Income-143.52-134.74-106.38-85.06-80.42
Interest Expense7.567.557.736.235.63
Unusual Expense7.042.67-2.650.000.00
Net Income Before Taxes-149.56-131.32-113.68-94.10-84.22
Income Taxes0.310.290.140.020.01
Consolidated Net Income-149.87-131.61-113.81-94.12-84.24
Net Income From Continuing Operations-149.87-131.61-113.81-94.12-84.24
Net Income-149.87-131.61-126.14-100.84-86.74
EPS (Recurring)-2.47-2.39-2.49-2.04-1.75
EPS (Basic, Before Extraordinaries)-2.67-2.43-2.46-2.04-1.75
EPS (Diluted)-2.67-2.43-2.46-2.04-1.75
EBITDA-134.18-126.03-98.41-73.50-75.57
Non-Operating Income (Expense)8.5613.64-2.21-2.801.83
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense30.4826.5819.171.180.96
Price To Sales Ratio12.5311.8020.65--
Gross Margin53.8951.3740.471.30-139.59
Operating Margin-134.48-141.64-177.85-305.83-1,054.01
Net Margin-140.43-138.36-210.88-362.55-1,136.79
Shares Outstanding59.2758.3851.3549.5349.53
Market Capitalization1,760.051,760.051,235.451,258.04-

Income statement, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q2
Total Revenue30.9728.6424.5522.5719.3717.2315.0914.71
Cost of Goods Sold Incl. D&A13.4712.9611.6511.1410.529.608.548.88
Gross Profit17.5015.6812.9111.428.857.636.555.83
Selling, General and Administrative Excl. Other55.1655.0347.6743.1837.7355.8427.1524.96
Research and Development6.805.634.974.884.005.393.353.51
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-37.66-39.34-34.77-31.75-28.88-48.21-20.60-19.13
Interest Expense1.931.841.891.901.911.761.781.44
Unusual Expense6.050.38-0.230.84-2.91-0.000.00
Net Income Before Taxes-44.04-38.64-34.13-32.75-25.79-51.01-21.74-20.61
Income Taxes0.050.190.040.030.030.100.020.01
Consolidated Net Income-44.09-38.84-34.17-32.78-25.83-51.11-21.76-20.62
Net Income From Continuing Operations-44.09-38.84-34.17-32.78-25.83-51.11-21.51-20.37
Net Income-44.09-38.84-34.17-32.78-25.83-54.40-24.83-23.69
EPS (Recurring)-0.68-0.66-0.61-0.63-0.54-1.06-0.48-0.48
EPS (Basic, Before Extraordinaries)-0.75-0.67-0.61-0.64-0.50-1.06-0.48-0.48
EPS (Diluted)-0.75-0.67-0.61-0.64-0.50-1.06-0.48-0.48
EBITDA-34.99-37.02-32.78-29.38-26.85-46.38-18.71-
Non-Operating Income (Expense)1.602.922.291.752.09-1.040.64-0.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.528.147.996.843.6217.630.36-
Price To Sales Ratio12.5312.7216.4618.9412.7520.65--
Gross Margin56.5054.7652.5750.6345.6944.2943.3939.63
Operating Margin-121.59-137.38-141.60-140.73-149.08-279.77-136.52-130.07
Net Margin-142.35-135.61-139.16-145.29-133.32-315.69-164.57-161.05
Shares Outstanding59.2758.3858.3551.4551.3551.3551.3549.53
Market Capitalization1,760.051,209.501,439.471,408.68847.251,235.451,258.04-

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments196.43237.598.2514.81
Short Term Receivables14.548.082.000.00
Inventories6.716.573.292.11
Other Current Assets4.683.081.371.50
Total Current Assets222.36255.3314.9118.42
Net Property, Plant & Equipment62.4536.9128.3916.72
Total Investments and Advances66.110.330.330.51
Deferred Tax Assets--4.603.11
Other Assets7.553.172.323.00
Total Assets358.46295.7450.5541.77
Short Term Debt Incl. Current Port. of LT Debt0.030.190.0021.81
Accounts Payable27.3023.9623.896.16
Other Current Liabilities23.0513.839.088.77
Total Current Liabilities50.3737.9832.9736.74
Long Term Debt46.7644.1245.1717.32
Provision for Risks Charges0.000.000.000.00
Deferred Tax Liabilities--4.673.17
Other Liabilities1.688.240.000.00
Total Liabilities98.8190.3482.8157.24
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.000.00177.11102.11
Common Equity259.66205.41-209.38-117.58
Total Shareholders Equity259.66205.41-32.27-15.47
Accumulated Minority Interest0.000.000.000.00
Total Equity259.66205.41-32.27-15.47
Total Liabilities & Stockholders Equity358.46295.7450.5541.77
Book Value Per Share4.454.00-4.23-2.37
Tangible Book Value Per Share4.454.00-4.23-2.37
Full-Time Employees443330--
Price to Book Ratio7.88-4.51-4.59-
Return on Assets-40.24-65.73-203.91-
Return on Equity-56.60-131.47--
Return on Invested Capital-42.95-45.61-729.50-4,543.58
Quick Ratio4.286.550.350.44
Current Ratio4.416.720.450.50

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-149.87-131.61-113.81-94.12-84.24
Depreciation9.358.717.9711.564.86
Other Funds (Non Cash)52.3839.2634.385.928.49
Funds from Operations-87.98-83.48-71.41-76.62-70.94
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital0.251.78-6.204.391.30
Cash from Operating Activities-87.72-81.70-77.61-72.23-69.64
Capital Expenditures-35.49-35.42-23.59-12.51-15.46
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.150.1817.380.280.00
Purchase or Sale of Investments-181.06-168.040.000.000.00
Purchase of Investments-181.06-168.040.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.00
Other Uses0.000.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities-216.40-203.28-6.21-12.23-15.46
Cash Dividends Paid-0.49-0.32-1.65-0.80-0.67
Change in Capital Stock151.32147.42314.8275.00102.11
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock151.32147.42314.8275.00102.11
Proceedsfrom Stock Options149.58146.82314.8275.00102.11
Issuance or Reduction of Debt, Net25.410.000.003.52-5.33
Change in Long Term Debt25.410.000.003.52-5.33
Issuance of Long Term Debt71.810.000.0042.650.00
Reduction of Long Term Debt-46.400.000.00-39.12-5.33
Net Financing Active Other Cash Flow-4.770.000.000.000.00
Other Financing Activities Uses-4.770.000.000.000.00
Cash from Financing Activities171.47147.09313.1677.7296.11
Net Change in Cash-132.66-137.88229.35-6.7411.00
Free Cash Flow-123.21-117.12-101.20-84.75-85.10
Preferred Dividends (Cash Flow)--0.32-1.65-0.80-0.67
Deferred Taxes & Investment Tax Credit-0.170.060.01-0.04

Balance sheet, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Cash & Short Term Investments198.91196.43291.32175.42201.21237.59
Short Term Receivables15.4114.5412.7110.419.258.08
Inventories7.446.716.836.926.806.57
Other Current Assets4.524.683.202.663.433.08
Total Current Assets226.27222.36314.06195.41220.69255.33
Net Property, Plant & Equipment66.9262.4557.2247.8942.4236.91
Total Investments and Advances46.1266.110.330.330.330.33
Other Assets8.047.557.733.062.853.17
Total Assets347.36358.46379.34246.70266.30295.74
Short Term Debt Incl. Current Port. of LT Debt0.020.030.010.050.040.19
Accounts Payable25.9627.3024.0220.2118.5723.96
Other Current Liabilities22.2923.0518.9015.4913.6513.83
Total Current Liabilities48.2750.3742.9335.7632.2637.98
Long Term Debt76.4246.7646.5444.7544.5544.12
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.311.681.892.125.338.24
Total Liabilities125.0098.8191.3582.6282.1490.34
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity222.36259.66287.99164.08184.16205.41
Total Shareholders Equity222.36259.66287.99164.08184.16205.41
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity222.36259.66287.99164.08184.16205.41
Total Liabilities & Stockholders Equity347.36358.46379.34246.70266.30295.74
Book Value Per Share3.754.454.943.193.594.00
Tangible Book Value Per Share3.754.454.943.193.594.00
Full-Time Employees-443---330
Price to Book Ratio7.884.207.747.634.12-4.51
Return on Assets-48.85-40.24-59.05-70.41--65.19
Return on Equity-73.74-56.60-97.73-136.96--130.38
Return on Invested Capital-14.76-12.67-10.21-15.70-11.29-20.48
Quick Ratio4.534.287.165.276.636.55
Current Ratio4.694.417.325.476.846.72

Cash flow, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Net Income-44.09-38.84-34.17-32.78-25.83-51.11
Depreciation2.662.331.982.372.031.84
Other Funds (Non Cash)16.6312.6911.7011.363.5028.97
Funds from Operations-24.79-23.65-20.48-19.05-20.29-20.24
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-7.504.932.120.71-5.98-3.46
Cash from Operating Activities-32.30-18.72-18.37-18.34-26.27-23.70
Capital Expenditures-8.34-9.66-9.99-7.50-8.27-8.04
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.070.080.040.28
Purchase or Sale of Investments-13.02-163.04-5.000.000.000.00
Purchase of Investments-13.02-163.04-5.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-21.35-172.71-14.92-7.42-8.23-7.76
Cash Dividends Paid-0.17-0.30-0.030.000.00-0.01
Preferred Dividends (Cash Flow)-0.17-0.30-0.030.000.00-0.01
Change in Capital Stock2.020.11149.21-0.03-1.88214.71
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.020.11149.21-0.03-1.88214.71
Proceedsfrom Stock Options0.88148.81-0.08-0.03-1.88214.71
Issuance or Reduction of Debt, Net25.410.000.000.000.000.00
Change in Long Term Debt25.410.000.000.000.000.00
Issuance of Long Term Debt71.810.000.000.000.000.00
Reduction of Long Term Debt-46.400.000.000.000.000.00
Net Financing Active Other Cash Flow-4.770.000.000.000.000.00
Other Financing Activities Uses-4.770.000.000.000.000.00
Cash from Financing Activities22.50-0.18149.18-0.03-1.88214.70
Net Change in Cash-31.15-191.61115.90-25.79-36.38183.24
Free Cash Flow-40.63-28.39-28.35-25.84-34.54-31.74

Revenue breakdown

Surgical & Medical Instruments & Apparatus2024: 59.82M 2025: 95.13M
United States2024: 59.82M 2025: 95.13M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3016.89%4.1M24.3M369.11K
2026-10-1514.11%3.4M24.3M338.32K
2026-09-3013.49%3.3M24.3M376.12K
2026-09-1512.85%3.1M24.3M375.67K
2026-08-3112.42%3.0M23.9M367.29K
2026-08-1412.60%3.0M23.9M371.96K
2026-07-3113.83%3.3M23.8M359.19K
2026-07-1516.41%3.1M18.9M347.96K
2026-06-3017.42%3.4M19.3M316.10K
2026-06-1515.19%2.9M19.3M342.68K
2026-05-2914.91%2.9M19.3M358.63K
2026-05-1516.84%3.3M19.5M354.96K
2026-04-3014.50%3.5M23.9M357.06K
2026-04-1515.20%3.6M23.9M349.86K
2026-03-3118.18%3.5M19.2M351.04K
2026-03-1314.57%2.8M19.2M300.07K
2026-02-2713.99%2.7M19.2M316.60K
2026-02-1312.64%2.4M19.2M320.11K
2026-01-3011.81%2.3M19.5M314.58K
2026-01-1511.59%2.3M19.5M318.23K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-054Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-03144Filing for proposed sale of securities under Rule 144.SEC
2026-10-29144Filing for proposed sale of securities under Rule 144.SEC
2026-10-294Statement of changes in beneficial ownership of securities2026-10-27SEC
2026-10-294Statement of changes in beneficial ownership of securities2026-10-27SEC
2026-10-28144Filing for proposed sale of securities under Rule 144.SEC
2026-10-27144Filing for proposed sale of securities under Rule 144.SEC
2026-10-27144Filing for proposed sale of securities under Rule 144.SEC
2026-10-224Statement of changes in beneficial ownership of securities2026-10-21SEC
2026-10-224Statement of changes in beneficial ownership of securities2026-10-20SEC
2026-10-21144Filing for proposed sale of securities under Rule 144.SEC
2026-10-20144Filing for proposed sale of securities under Rule 144.SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-09-30144Filing for proposed sale of securities under Rule 144.SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-21144Filing for proposed sale of securities under Rule 144.SEC
2026-09-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-07-31SEC
2026-09-148-KCurrent report2026-09-14SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-108-KCurrent report2026-09-09SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-17SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110094.35K1
2026-10006.47M6
2026-0900608.63K6
2026-08003.76M11
2026-07001.96M11
2026-0600312.14K1
2026-0500314.33K1
2026-0400300.67K1
2026-03199.80K1304.12K1
2026-0200384.02K1
2026-0100342.02K1
2025-1200679.05K2
2025-110000

Institutional holders

Manager% owned
BAIN CAPITAL INVESTORS LLC43.12%
FMR LLC10.00%
PRICE T ROWE ASSOCIATES INC /MD/8.51%
Andera Partners4.58%
Yu Fan3.91%
BROWN ADVISORY INC3.27%
BlackRock, Inc.3.20%
ALLIANCEBERNSTEIN L.P.2.53%
EVENTIDE ASSET MANAGEMENT, LLC2.48%
VANGUARD CAPITAL MANAGEMENT LLC2.01%

Funds

Fund% owned
Eventide Healthcare & Life Sciences Fund2.34%
Franklin Small Cap Growth Fund1.46%
iShares Russell 2000 ETF1.19%
AB Small Cap Growth Portfolio1.05%
Federated Hermes Kaufmann Small Cap Fund0.97%
SmallCap Growth Fund I0.77%
Osterweis Opportunity Fund0.53%
Brown Advisory Small-Cap Growth Fund0.51%
iShares Russell 2000 Growth ETF0.43%
Hood River New Opportunities Fund0.41%

OakChart. KMTS. Cached 15 minutes.